Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
-Patients who are being evaluated or are on research protocols at the NIH Clinical Center
will be entered onto this tissue procurement protocol for collection of tissue specimens.
- To obtain samples for research purposes from tests performed for clinical & research
indications on other research protocols.
- To obtain samples for research purposes from non-surgical procedures, such as
percutaneous biopsies, performed for the sole purpose of obtaining biological fluids
for this protocol.
-Patients who are being evaluated for and/or treated on research protocols at the NIH
- Specimens for research purposes, as outlined in this protocol, will be obtained from
tests and procedures that are done as required by the primary research protocols that a
given patient is enrolled in.
- Non-surgical procedures, such as percutaneous biopsies, may also be performed for the
sole purpose of obtaining tissue specimens or biological fluids for this protocol.
-Given the risks associated with any invasive procedure, such as tumor biopsy, the
procedure will be discussed in detail with the patients, including the side effects, prior
obtaining a separate consent for each procedure. A separate consent will not be signed
prior to obtaining samples obtained by minimally invasive measures, such as blood.
-Tissues and biological fluids to be procured may include but are not limited to blood,
serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar
lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens
will be stored with unique identifier and used to perform only those research studies that
are outlined in this protocol.
-This study has two separate consent forms. Patients can opt to donate their samples for
ongoing research on assay development and studying pathways. In addition, patients can opt
to donate samples to create preclinical models to study tumor biology and genetics, and to
develop new therapies for cancer.
-Patients may remain on study for the duration of their consent.
Shivaani Kummar, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda, Maryland 20892|